Exclusion Criteria:~* Non-Alzheimer primary dementia diagnosis (e.g., vascular dementia, Lewy body dementia,
frontotemporal dementia, vitamin B-12 deficiency, hypothyroidism).~* Diagnosis of any of the following
conditions; major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia,
or delusional disorder as defined by Diagnostic and Statistical Manual (DSM)-IV.~* Diagnosis of systemic
illnesses that would interfere with participation in the study or decrease the life expectancy to less than one
year.~* Currently being treated with hydralazine or a history of intolerance to oral therapy with hydralazine~*
Any intravenous treatment for heart failure, except IV furosemide (e.g. IV inotropes, pressors, nitrates or
nesiritide) at the time of screening.~* Systolic blood pressure <100 mmHg, reversible etiology of acute heart
failure such as myocarditis, acute myocardial infarction-over the past 4 weeks, arrhythmia and existence of
pacing device (Acute myocardial infarction is defined as symptoms and major electrocardiogram (ECG) changes
(i.e., ST segment elevations), and arrhythmia includes unstable heart rates above 120/min or below 50/min).~*
Existence of severe congenital heart disease (such as uncorrected tetralogy of fallot or transposition of the
aorta) and severe aortic or mitral stenosis or severe rheumatic mitral regurgitation.~* Concurrent use of
phosphodiesterase type 5 (PDE5) inhibitors (e.g. Viagra, Etc.)~* Cardiac revascularization within the last 3
months or likelihood of requiring coronary revascularization within the study period. eGFR (Glomerular
Filtration Rate) < 15ml/min/1.73m2, or on regular dialysis, or planned dialysis within the study period.
